Julio Ramirez
Infectious Disease · Louisville, KYNPI 1225016983
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Pfizer accounts for 71.7% of it on its own, with 19 other manufacturers making up the rest. Among infectious disease clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 164 payments — averaging $1560.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$183K
- Paratek Pharmaceuticals, Inc.$26K
- Pfizer Chile S.A.$21K
- Dompe US, Inc.$8K
- Genentech, Inc.$4K
- Pfizer S.A.$4K
- plus $9K from 14 others
Across 306 payments — averaging $60,612 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$17.5M
- Janssen Research & Development, LLC$530K
- Eli Lilly$282K
- Sanofi Pasteur Inc.$188K
- Dompe Farmaceutici S.p.a.$10K
- Gilead$5K
- plus $792 from 1 others
What the payments were for
- Consulting fees$95,35137%
- Speaking & faculty fees$93,76737%
- Travel & lodging$62,82625%
- Food & beverage$3,7621%
- Education$2160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer(2 entities) | 74 | $183,464 |
| Paratek Pharmaceuticals, Inc. | 17 | $25,801 |
| Pfizer Chile S.A. | 6 | $20,652 |
| Dompe US, Inc. | 4 | $8,400 |
| Genentech, Inc. | 5 | $4,496 |
| Pfizer S.A. | 3 | $4,403 |
| Melinta Therapeutics, LLC | 6 | $2,971 |
| AbbVie(2 entities) | 11 | $2,246 |
| Eli Lilly | 1 | $1,050 |
| GSK | 1 | $999 |
| Valneva USA, Inc. | 1 | $391 |
| Nabriva Therapeutics, PLC | 1 | $295 |
| Astellas Pharma US Inc | 8 | $266 |
| Insmed, Inc. | 3 | $148 |
| Gilead | 8 | $124 |
| Merck | 7 | $95 |
| Tetraphase Pharmaceuticals, Inc. | 3 | $41 |
| Johnson & Johnson | 3 | $40 |
| Novo Nordisk | 1 | $27 |
| Viiv Healthcare Company | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$255,922 in reported general payments places this provider in the 95th percentile of 100 infectious disease providers in Kentucky.
Other infectious disease in Louisville
- Martin GnoniLouisville$194K
- Paul SchulzLouisville$189K
- Tariq MehmoodLouisville$75K
- Anupama RaghuramLouisville$9K
- Barbara WojdaLouisville$7K
- Benjamin KlausingLouisville$7K
- Kamran AkhtarLouisville$4K
- Forest ArnoldLouisville$4K
- Mark BurnsLouisville$3K
- Kenechukwu ObiokoyeLouisville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.